Roivant Sciences (NASDAQ:ROIV) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Roivant Sciences (NASDAQ:ROIV) in a research note released on Thursday morning, Benzinga reports. HC Wainwright currently has a $18.00 price objective on the stock.

Several other analysts also recently commented on the stock. Cantor Fitzgerald restated an overweight rating on shares of Roivant Sciences in a research report on Monday, September 9th. Bank of America raised their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a neutral rating in a research report on Wednesday, September 11th. Finally, Piper Sandler raised their price objective on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an overweight rating in a research report on Wednesday, July 10th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $17.39.

Roivant Sciences Stock Up 0.4 %

ROIV opened at $11.97 on Thursday. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05. Roivant Sciences has a 1-year low of $8.24 and a 1-year high of $13.24. The company has a market capitalization of $8.84 billion, a PE ratio of 2.37 and a beta of 1.25. The firm’s 50 day simple moving average is $11.46 and its two-hundred day simple moving average is $11.05.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.33. The firm had revenue of $55.10 million for the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The company’s revenue was up 155.1% on a year-over-year basis. During the same period last year, the firm earned ($0.38) EPS. As a group, equities analysts forecast that Roivant Sciences will post -1.14 EPS for the current year.

Hedge Funds Weigh In On Roivant Sciences

Institutional investors and hedge funds have recently made changes to their positions in the business. nVerses Capital LLC purchased a new position in shares of Roivant Sciences in the 2nd quarter worth $34,000. Point72 Hong Kong Ltd purchased a new position in shares of Roivant Sciences in the 2nd quarter worth $36,000. Quarry LP purchased a new position in shares of Roivant Sciences in the 2nd quarter worth $53,000. Acadian Asset Management LLC purchased a new position in shares of Roivant Sciences in the 1st quarter worth $72,000. Finally, Fifth Third Wealth Advisors LLC purchased a new position in shares of Roivant Sciences in the 2nd quarter worth $101,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.